newsfilter
← Earnings
Earnings Releases·

Capricor Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 operating expenses rose to $44.7 million from $26.3 million in Q3 2025, driving a net loss of $42.7 million ($0.73/share) versus $24.6 million ($0.54/share) previously; cash reserves declined to $198.5 million as of September 30, 2026, from $318.1 million at year-end 2025.
  • The Deramiocel BLA for Duchenne muscular dystrophy remains under FDA review with a PDUFA date of November 22, 2026, following a major amendment submission that extended the review period by three months.
  • Management confirmed current cash is sufficient to fund operations for at least the next twelve months, while prioritizing Deramiocel development and deprioritizing other programs like the StealthX exosome platform pending U.S. regulatory outcomes.
  • A 10% workforce reduction was implemented in Q3 to lower expenses, and the company is pursuing arbitration against Nippon Shinyaku regarding distribution rights, with a hearing expected in mid-2027.
Company
CAPRICOR THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology